The progress has been encouraging with approvals and launches in the US, EU, Japan, Australia and Emerging Markets. Post Mylan Upjohn (Pfizer) merger, the scope has been extended to China as well.
The merger is in line with Solara’s strategy of accelerating growth via appropriate inorganic actions
The jump in profit is due to the better performance of the API business.
The partnership is a significant step in delivering advanced cancer therapies to patients.
With cost optimization leading to cumulative savings of US $80 million over last 8 years, the company now aims to tap bigger opportunities in generics business
With a mix of vaccines targeting different stages of COVID-19, the company is eyeing huge market potential
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
